SITE003-0384

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2023-05-23

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-06-29 (study day 17); relationship: not assessed

severe assessed

Grade 3 Fatigue — outcome: UNKNOWN; onset 2023-07-07 (study day 25); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-04 (study day 114); relationship: Y

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-13 (study day 123); relationship: not assessed

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-11-19 (study day 160); relationship: not assessed

severe serious assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-12-16 (study day 187); relationship: not assessed; serious criteria: hospitalization

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2024-02-05 (study day 238); relationship: N

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-03-30 (study day 292); relationship: not assessed

Data queries

No data queries.